the pause that refreshes

Todays announcement of the Poster Presentation of preliinary results from the BNC 105 trials was apathetic.

This drug is more advanced than BNC210 an dhas much greater dollar sales potential.

BNO's latest presentation material suggests that the company anticipates an upfront payment of $50m to licence BNC 210 but $75m for BNC 105.

The stock has had a great run, asisted by the Startup Australia tender an dmay need a pause or period of consolidation.

However, the news flow is not about to stop.

Southern Cross Equities has a juicy near term target price and so too does Eddison Research.

Pullback is normal an dhealthy market reaction and an opportunity for laggards to get on board.

DYOR.